biotech · Pediatric acute-onset neuropsychiatric syndrome (PANS) · acute hereditary angioedema attacks · MAZE
Maze Therapeutics
Maze Therapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2018
- Employees
- 152
- Programs
- 8
- Drugs
- 12
- Patents
- 60
Maze Therapeutics projects
8 ClinicalTrials.gov programs sponsored by Maze Therapeutics.
Maze Therapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CONE-02
Maze Therapeutics
acute hereditary angioedema attacks
1 trial -
NGAM-12
Maze Therapeutics
Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia.
1 trial -
NGAM-13
Maze Therapeutics
Pediatric acute-onset neuropsychiatric syndrome (PANS)
1 trial -
NGAM-16
Maze Therapeutics
Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.
1 trial -
Newnorm
Maze Therapeutics
Human Normal Immunoglobulin
1 trial -
MZE829
Maze Therapeutics
APOL1 Kidney Disease (AKD)
1 trial -
MZE829
Maze Therapeutics
Proteinuric Kidney Disease
1 trial -
MZE001
Maze Therapeutics
Healthy
1 trial
Frequently asked questions
How many clinical projects does Maze Therapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.